Subsequent Events (Details) - Subsequent Event - Ligand Pharmaceuticals Incorporated - Xoma Royalty Corporation $ / shares in Units, $ in Millions |
Apr. 27, 2026
USD ($)
$ / shares
|
|---|---|
| Business Combination, Description | |
| Business combination, date of acquisition agreement | Apr. 27, 2026 |
| Business combination, name of acquiree | XOMA Royalty Corporation |
| Business combination, price per share (in dollars per share) | $ / shares | $ 39 |
| Business combination, price of acquisition, expected | $ | $ 739.0 |
| Business combination, contingent value rights per share | 1 |
| Percentage share of net proceeds that may result from ongoing litigation (as a percent) | 75.00% |
| X | ||||||||||
- Definition Date when acquisition agreement is executed in business combination, in YYYY-MM-DD format. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Name of acquiree in business combination. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Per share price of saleable stock paid or offered to be paid by acquirer in business combination. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Purchase price of expected business acquisition prior to consideration being transferred. Excludes asset acquisition. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Business Combination, Contingent Value Rights Per Share No definition available.
|
| X | ||||||||||
- Definition Percentage Share of Net Proceeds That May Result From Ongoing Litigation No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|